Swedish Orphan Biovitrum AB (CHIX:SOBIS) Cyclically Adjusted Revenue per Share: kr60.25 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:SOBIS Swedish Orphan Biovitrum AB CHIX:SOBIS
84 GF Score
Price kr465.60
GF Value kr360.53
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Swedish Orphan Biovitrum AB Cyclically Adjusted Revenue per Share?

Swedish Orphan Biovitrum AB CHIX:SOBIS 84 Cyclically Adjusted Revenue per Share is kr60.25 as of Jun. 2026. GuruFocus rates CHIX:SOBIS with a GF Score™ of 84/100 and a GF Value™ of kr360.53 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Swedish Orphan Biovitrum AB's adjusted revenue per share for the three months ended in Jun. 2026 was kr22.402. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr60.25 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Swedish Orphan Biovitrum AB's average Cyclically Adjusted Revenue Growth Rate was 13.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 16.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 21.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Swedish Orphan Biovitrum AB was 25.90% per year. The lowest was 16.50% per year. And the median was 23.20% per year.

As of today (2026-07-26), Swedish Orphan Biovitrum AB's current stock price is kr465.60. Swedish Orphan Biovitrum AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was kr60.25. Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio of today is 7.73.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Swedish Orphan Biovitrum AB was 21.25. The lowest was 4.89. And the median was 7.12.


Swedish Orphan Biovitrum AB  (CHIX:SOBIs) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=465.60/60.25
=7.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Swedish Orphan Biovitrum AB was 21.25. The lowest was 4.89. And the median was 7.12.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Swedish Orphan Biovitrum AB Cyclically Adjusted Revenue per Share Related Terms


Swedish Orphan Biovitrum AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Swedish Orphan Biovitrum AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Swedish Orphan Biovitrum AB Cyclically Adjusted Revenue per Share Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.38 38.77 39.93 51.57 55.18

Swedish Orphan Biovitrum AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.94 54.41 55.18 58.43 60.25

CHIX:SOBIS vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Cyclically Adjusted PS Ratio falls into.


CHIX:SOBIS
84GF Score
Swedish Orphan Biovitrum AB CHIX:SOBIS
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Swedish Orphan Biovitrum AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Swedish Orphan Biovitrum AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=22.402/134.1100*134.1100
=22.402

Current CPI (Jun. 2026) = 134.1100.

Swedish Orphan Biovitrum AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 4.157 101.138 5.512
201612 4.584 102.022 6.026
201703 4.944 102.022 6.499
201706 5.796 102.752 7.565
201709 5.665 103.279 7.356
201712 6.621 103.793 8.555
201803 6.939 103.962 8.951
201806 8.074 104.875 10.325
201809 8.171 105.679 10.369
201812 9.078 105.912 11.495
201903 10.781 105.886 13.655
201906 10.224 106.742 12.845
201909 9.458 107.214 11.831
201912 15.762 107.766 19.615
202003 14.913 106.563 18.768
202006 9.873 107.498 12.317
202009 9.537 107.635 11.883
202012 14.626 108.296 18.112
202103 11.706 108.360 14.488
202106 10.361 108.928 12.756
202109 12.110 110.338 14.719
202112 15.713 112.486 18.734
202203 15.814 114.825 18.470
202206 12.425 118.384 14.076
202209 12.589 122.296 13.805
202212 19.428 126.365 20.619
202303 16.717 127.042 17.647
202306 15.521 129.407 16.085
202309 16.211 130.224 16.695
202312 19.960 131.912 20.293
202403 18.183 132.205 18.445
202406 15.788 132.716 15.954
202409 19.876 132.304 20.147
202412 21.426 132.987 21.607
202503 18.633 132.825 18.813
202506 17.787 133.699 17.842
202509 22.353 133.480 22.459
202512 22.432 133.390 22.553
202603 20.561 133.560 20.646
202606 22.402 134.110 22.402

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr60.25 mean?
Swedish Orphan Biovitrum AB (CHIX:SOBIS) has a Cyclically Adjusted Revenue per Share of kr60.25 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Swedish Orphan Biovitrum AB and its competitors.
Is Swedish Orphan Biovitrum AB's Cyclically Adjusted Revenue per Share too high?
Swedish Orphan Biovitrum AB's current Cyclically Adjusted Revenue per Share is kr60.25. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Swedish Orphan Biovitrum AB's Cyclically Adjusted Revenue per Share of kr60.25 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Swedish Orphan Biovitrum AB and its competitors. Swedish Orphan Biovitrum AB's current Cyclically Adjusted Revenue per Share is kr60.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (CHIX:SOBIS) is currently considered Modestly Overvalued. The stock's GF Value™ is kr360.53, compared to a current price of kr465.60 — trading 29.1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr60.25. Swedish Orphan Biovitrum AB's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (CHIX:SOBIS), the current Cyclically Adjusted Revenue per Share is kr60.25 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Swedish Orphan Biovitrum AB (CHIX:SOBIS) Overvalued in 2026?

Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued. The current stock price of kr465.60 is trading 29.1% above its estimated GF Value™ of kr360.53. GuruFocus considers Swedish Orphan Biovitrum AB to be Modestly Overvalued.

Key valuation signals for CHIX:SOBIS:

  • Cyclically Adjusted Revenue per Share: kr60.25
  • GF Value™: kr360.53 vs. price of kr465.60 (29.1% above fair value)
  • GF Score™: 84/100 with 6 warning signs

No single metric tells the full story. See the CHIX:SOBIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Swedish Orphan Biovitrum AB Business Description

Address Norra Stationsgatan 93A, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
84GF Score

Get the complete analysis for CHIX:SOBIS

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr465.60
Price
kr360.53
GF Value